Medtronic conducted a post market clinical follow-up (pmcf) survey to seek out potential new risks and assess the performance of medtronic¿s pacific plus pta balloon catheter.
Survey results received for an interventional cardiologist with 20 years¿ experience.
The respondent has been using medtronic¿s pacific plus pta balloon catheter since (b)(6) 2019.
Overall, the respondent has used medtronic¿s pacific plus pta balloon catheter in a total of 60 procedures since beginning to use the system all of which have been carried out within the past 12 months.
Of these procedures, the devices were used for dilatation of stenoses in patients with obstructive disease in iliac arteries (10), femoral arteries (10), iliofemoral arteries (10), popliteal arteries (10), infrapopliteal arteries (10), renal arteries (5), and 5 during treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae.
The respondent has not used medtronic's pacific plus pta balloon catheter in any other anatomical locations other than those described above.
The respondent reports complications death associated specifically with angiography.
These events were deemed as being device related.
The complications of death were considered as being very concerning.
|